This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Rigel Pharmaceuticals, Inc.
Drug Names(s): R926112
Description: R112 enters mast cells, binds to an intracellular target and interrupts the signal from the IgE receptor, thus preventing downstream signaling and subsequent chemical mediator release.
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: